|
市場調查報告書
全球生物醫藥市場趨勢
THE WORLD BIOTECH MARKET REPORT 2005
| 出版商 |
Visiongain |
| 出版日期 |
2005年07月 |
商品編碼 |
32497 |
| 內容資訊 |
英文 300 pages, 70 tables, 80 graphs & charts |
| 價格 |
|
|
本報告已在2011年07月19日停止出版。
The biopharmaceutical market has expanded rapidly. No longer is it confined to growth hormones, insulin and red blood cell stimulating agents. Innovative science is accelerating the market into targeting a huge range of diseases from growth deficiency to arthritis, to multiple sclerosis and orphan diseases such as Fabrys disease. Are you part of this world market? Is your organisation profiting as much as it should? A brand new report is here to help you. Visiongains Exclusive World Biotech Market report analysis in-depth the value of the 2005 biopharma market. Having grown 16.5 per cent from 2004s revenues, double-digit growth of the market will continue to the end of the decade. You need to be aware of how you can succeed in this area. Composed of 9 major therapeutic areas, the market is expected to represent 17% of all prescriptions written by 2010. At this rate, biotech is now outgrowing Big Pharma - you must be informed TODAY. Biotech companies however still
face major challenges. The threat of the emergence of biogenerics is mounting, with 11 products facing patent expiry before 2007 - 5 of which are blockbusters. The Australian approval of his Sandozs Omnitrope hGH product is paving the way, and increasing pressure upon EU and US regulatory agencies to give the go ahead to biogenerics. Your competitors will be reading this report - you need to too.
Designed as an essential business aid, World Biotech Report 2005 provides the leading thorough evaluation of your market. This extensive report focuses on the following aspects:
- 1. Diseases treated by Biopharmaceuticals
- 2. In-depth analysis of succeeding in the Biopharmaceuticals Market
- 3. Current Company Revenues and Market Share, 2004
- 4. Biopharmaceutical Pipeline, 2005
- 5. Unique Biopharmaceutical Market Forecasts, specifically by Therapeutic Area, 2003-2010
- 6. A focus on the 2010 Biopharmaceuticals Market - plan to succeed now
- 7. The threat of Biogenerics
- 8. Is there an opportunity for you in the Biogeneric Market
- 9. Overcoming the Biopharmaceutical Market Challenges
- 10.Venture Capitalism and Biotech
The report provides you with in-depth market analysis for all top-selling current and major potential products to arrive before the decade ends. The report extensively identifies biopharmaceuticals market potential by analysing the latest clinical trial research. The study also examines the challenges faced by potential biotech companies and opportunities newcomers to the arena. This is the industrys premier report. Numbers are strictly limited.
Why You Must Buy This Report?
This 300 page report spanning 13 chapters features over 70 tables, 80 graphs and charts, news, insights and visiongain consultants critical opinion on leading developments. Over 120 companies are mentioned in this critical report, which reviews 2004 revenues for ALL the biopharmaceutical products featured within the market. Due to visiongains targetted consultancy work in the area, only a strict number of these reports are issued. Please order your copy now so as you do not miss out. Copies will be reserved on a strictly first-come-first-serve basis. So please contact us now.
Five key questions this report answers are:
- 1. What are the market values of the major therapeutic areas of the global biopharmaceutical market by product from, 2004 to 2010?
- 2. Who are the major companies involved in the world market today and in the future?
- 3. How imminent are biogenerics and what is their potential market value?
- 4. What strategies can be used to maximise profits in terms of the major challenges facing biotech?
- 5. Whats in the 2005 biopharmaceutical pipeline and what revenues can they reach by 2010?
Chapter 1: Executive Summary of World Biotech Market, 2005
- 1.1 Abstract of Biotech, 2005
- 1.2 Aims, Scope and Format of Biotech, 2005
Chapter 2: Introduction to Biotechnology
- 2.1 What is Biotechnology?
- 2.2 The Uniqueness of Biopharmaceuticals: Turning Medicine Around
- 2.3 Biotechnologies Used and Their Applications to Pharma
- 2.3.1 Bioprocessing Technology
- 2.3.2 Monoclonal Antibodies
- 2.3.3 Recombinant DNA Technology
- 2.3.4 Cloning
- 2.3.4.1 Molecular Cloning
- 2.3.4.2 Cellular Cloning
- 2.3.4.3 Animal Cloning
- 2.3.4.4 Protein Engineering
- 2.4 The Future Biopharmaceutical Market
- 2.4.1 Biopharmaceutical 2004 Market Capatilisation Worth $311bn
- 2.4.2 Over 7000 Biotechnology Patents Granted Per Annum Since 1998
- 2.4.3 2004 Witnessed 54 New Biopharmaceuticals Approved by the FDA
- 2.4.4 Biopharmaceuticals Share 12.5% of 2004 Global Prescriptions
Chapter 3: Diseases Treated by Biopharmaceuticals
- 3.1 Biopharmaceuticals Are Versatile Agents
- 3.2 Orphan Diseases Are A Major Target of Biotech: 3 Out of 10 2004 Orphan Disease Drug Approvals Were
- Biopharmaceuticals
- 3.3 Overview of Major and Orphan Diseases Treated By Biopharmaceuticals, 2005
Chapter 4: Overview of Biopharmaceuticals Market, 2003-2004
- 4.1 Monoclonal Antibodies: Leading Class of Biopharmaceuticals in 2004 With Sales of $13bn
- 4.2 Biopharmceuticals by Therapy Class: Blood Disorders Share Over A Quarter of the 2004 Biopharmaceuticals Market
- 4.3 2004 Biopharmaceuticals Market Worth a Staggering $55.7bn
- 4.4 The Top 20 Selling Biopharma Drugs of 2004 Accounted For 62% of Total Revenues
- 4.5 The Top 3 Biopharmaceuticals Products of 2004 Sold Over $9bn
- 4.5.1 Procrit/Eprex - The Number One Biopharmaceutical Struggles at the Top
- 4.5.2 Risperdal Performs Well Thanks to New Delivery Technology
- 4.5.3 Epogen: The Third Best Selling BiopharmDrug of 2004
- 4.6 Santura: The Highest Earning Newcomer of 2004
Chapter 5: Company Revenues and Market Share, 2004
- 5.1 Amgen: The Reign Continues With A 17% Share of 2004 Market
- 5.1.1 Who Are Amgen?
- 5.2 Biotech Company Winners and Losers in 2004: Abbott, Sanofi-Aventis and Roche
- 5.3 BMS: The Best Company Newcomer of 2004
- 5.4 Biotech Companies Show High Growth Rates
Chapter 6: Biopharmaceutical Pipeline
- 6.1 Technology Driving Biopharma Pipeline
- 6.2 Biotech Targeting Chronic Illness
- 6.3 Arthritis Biopharmaceutical Pipeline, 2005
- 6.4 MS Biopharmaceutical Pipeline, 2005
- 6.5 Late-Stage Biopharmaceutical Oncology Pipeline, 2005
- 6.6 Late StageBiopharmaceutical Vaccine Pipeline, 2005
- 6.7 Blood Disorders Biopharmaceutical Pipeline, 2005
- 6.8 Late Stage Biopharmaceutical Endocrine Pipeline, 2005
- 6.9 Anti-Infectives Biopharmaceutical Pipeline, 2005
- 6.10 Enzyme Deficency Biopharmaceutical Pipeline, 2005
- 6.11 Late Stage Biopharmaceutical Opthalmic Pipeline, 2005
- 6.12 Late Stage Biopharmaceutical Other Pipeline, 2005
Chapter 7: Biopharmaceutical Market Forecast by Therapeutic Area, 2003-2010
- 7.1 Blood Disorders
- 7.2 Endocrine Disorders
- 7.3 Multiple Sclerosis
- 7.4 Oncology
- 7.5 Anti Infectives
- 7.6 Enzyme Deficiency Disorders
- 7.7 Vaccines
- 7.8 Arthritis
- 7.9 Opthalmics
- 7.10 Others
- 7.11 Biopharmaceutical Market Set To Almost Triple By 2010
Chapter 8: Summary of 2010 Biopharmaceuticals Market
- 8.1 Aransep: The Top Selling Biopharmaceutical of 2010 With Sales of $5.2bn
- 8.2 Blood Disorders Will Reamain Market Leaders
- 8.3 Ophthalmic Biopharmaceuticals: The Fastest Growing Therapeutic Class 2003-2010
- 8.4 By 2010 Biopharmaceuticals Will Account for Over 17% of All Drug Prescriptions
- Chapter 9: Introduction to Biogenerics
- 9.1 What are Biogenerics?
- 9.2 The Biogeneric Threat Looms Large
- 9.3 All Change in 2003: CDER to CBER
- 9.4 How are Approval Pathways Limiting the Development of Biogenerics?
- 9.5 Omnitrope Approved in Australia, Will Europe and the US Follow?
- 9.6 High Cost of Market Entry
- 9.7 Manufacturing Capacity Problems
- 9.8 Biopharma Vs Biogenerics: The Fight Continues
- 9.8.1 Bioequivalence or Biosimilarity?
- 9.9 Will the Benefits of Biogenerics be as Great as Anticipated?
- 9.10 How Imminent is the Threat from Biogeneric Competition?
Chapter 10: The Potential Biogeneric Market
- 10.1 $13bn of Biopharmaceuticals To Lose Patency Protection By 2007
- 10.2 Eleven Biopharmaceuticals to Face Patent Expiry by 2007
- 10.3 High-Revenue Generating Biopharmaceuticals Face Patent Expiry Before 2007
- 10.4 High-Profile Biopharmaceuticals With Patent Expirations Before 2007 Revenue Forecast, 2003-2010
- 10.5 Erythropoiteins Are Most At Risk To Biogeneric Competition
Chapter 11: Biopharmaceutical Market Challenges
- 11.1 BioTechs Delivery Challenge
- 11.1.1 Pulmonary Delivery: An Innovative Alternative to the Needle?
- 11.1.2 The Major Issues of the Pulmonary Pathway
- 11.1.3 Does Protein Formulation Affect Pulmonary Delivery?
- 11.1.4 Does Pulmonary Drug Delivery Have a Future?
- 11.1.5 Pegylated Forms Set to Revolutionise Delivery
- 11.1.6 Pegylation Can Extend Patencies! The Filgrastim Example
- 11.1.7 Transdermal Technologies
- 11.1.8 Microneedles for Transdermal Delivery of Vaccines
- 11.1.9 Nasal Delivery Is Demonstrating Promise
- 11.1.10 Moving Towards Pills? Altus Unique Technology
- 11.1.11 New Delivery Technologies: A Pharmacy or Medical Benefit?
- 11.1.12 Innovative Insulin Delivery Technology: The Race is On!
- 11.1.13 Numerous Potential Blockbusting NonInjected Insulins Set to Arrive 2005-2009
- 11.2 Manufacturing Capacity Shortfall
- 11.2.1 Why is There a Shortfall in Manufacturing Capacity for Biopharmaceuticals?
- 11.2.2 Make Vs. Buy: The 1980s BioIndustry
- 11.2.3 CMO Manufacturing Capacity was Adequate for the Supply of Clinical Materials Only
- 11.2.4 Late-Stage Products have absorbed CMO Clinical Manufacturing Capacity
- 11.2.5 How is the Manufacturing Capacity Shortfall Being Overcome?
- 11.2.6 Does The Future for Biopharmaceuitcal Manufacturing Lie with Transgenics?
- 11.3 The Cost of Biopharmaceuticals
- 11.3.1 The Top Five Biopharmaceuticals Each Cost at Least $10K Per Patient Per Annum
- 11.3.2 Monoclonal Antibodies and CSFs High Costs Reflect Production Difficulties
- 11.3.3 Yeast-Based Systems May Bring Down the Cost of Therapeutic Proteins in the Future
- 11.4 Acquiring Capital
- 11.4.1 Financing of Biotech Companies in 2003 Neared $17bn
- 11.5 Reliance Upon University/Company Collaborations
- 11.5.1 The Need For Collaboration
- 11.5.2 Biotechs Increasing Role of Commercialising University Research
- 11.5.3 Future Biotech Innovation Lies With Academia
- 11.5.4 The Risky Path from Bench to Market
- 11.5.5 Collaboration Strategies & Becoming the Partner of Choice
- 11.5.5.1 Objectives That Support Strategic Goals
- 11.5.5.2 Understanding the Value Brought to an Alliance
- 11.5.5.3 Identifying and Understanding Potential Partners
- 11.5.5.4 Due Diligence
- 11.5.5.5 Promoting Capabilities to Potential Partners
- 11.5.5.6 Maintaining a Relationship Through Structured Interactions
- 11.5.5.7 Gaining Competitive Advantage
- 11.5.5.8 Collaboration Management: Developing and Maintain A Deal
- 11.5.5.9 Strategic Goals to Consider
- 11.6 Regulatory Issues
- 11.6.1 Biopharmaceuticals and the FDA
- 11.6.2 FDA Improving Upon Biologics Approval Wait
- 11.7 Biogeneric Threat
- 11.8 Dependence upon Venture Capital Investment
- 11.9: Drivers and Restraints of Biopharmaceutical Market Growth
- 11.9.1 Drivers
- 11.9.2 Restraints
Chapter 12: Venture Capital Investment & Biotech
- 12.1 What is Venture Capital Investment?
- 12.2 What does VC Offer?
- 12.3 What Do Venture Capitalists Do?
- 12.4 Who Are Venture Capitalists?
- 12.4.1 Banks as Venture Capitalists
- 12.4.2 Business Angels (Wealthy Individuals) as Venture Capitalists
- 12.4.3 Corporate or Direct Investors as Venture Capitalists
- 12.4.4 Government Grants and Governments as Venture Capitalists
- 12.4.5 Venture Capital Firms
- 12.4.6 Other Types of Venture Capitalists
- 12.5 Why Do Biotech Companies Need VC Funding?
- 12.6 Venture Capital Investment in the US Biotech Market
- 12.6.1 US VC Investment Now Recovering Following Stockmarket Crash in 2000
- 12.6.2 329 US Biotech VC Investments Made in 2004, Providing Over $3.8bn
- 12.6.3 Synta Provides 2004s Largest US Investment Sum With $80m
- 12.6.4 MPM Capital 2004s Most Active US Biotech VC Firm
- 12.6.5 Company Expansion Stage is the Most Favourable for VC Investment
- 12.7 Increase in VC Funding of European Biotech
- 12.8 PE European Investments in Biotech Followed Similar Trends as in the US
- 12.9 European PE Biotech Investments are a Small part of the Funding Market
Chapter 13: The Global Biopharmaceutical Market by Region, 2003-2010
- 13.1 The World Biopharmaceutical Market is Dominated by the US
- 13.2 Both the Japanese and European Biotech World Market Share Set to Fall by 2010
13.3 The US Biotech Market Will Retain Its World Dominance
- 13.4 The European Biotech Market Will See Reduced Growth
- 13.5 European Biotech Industry Faces VC Funding Drop
- 13.6 Price Cuts in Japanese Biotech Market
- 13.7 Asia-Pacific Region: A Dormant Giant?
- 13.8 Biotech Industries in the Asia-Pacific Region are Growing Rapidly
- 13.9 China has the Most Biotech Companies in the Asia-Pacific region
- 13.10 Other World Markets
- 13.10.1 Russia Will See Growth in Biopharma Generics
- 13.10.2 Israel is and Area of Biotech Industry More than a Market for Biotech Drugs
Chapter 14: The Human Genome Project and Its Influence on the Biotech Industry
- 14.1 Applications and Future Developments of the HGP
Chapter 15: Conclusion: Big Pharma Must Invest into the Biotech Arena
- 15.1 Conclusion
|
